Arcadia Biosciences (RKDA) Q3 2025 earnings summary

Executive summary

• Focus shifted to Zola coconut water after divesting wheat-related assets and brands, including the sale of GoodWheat and RS durum wheat trait in 2024, and transfer of soy trait rights in 2025.

• Zola coconut water revenues grew 26% year-to-date, offsetting the absence of $700,000 in GLA sales from 2024.

• Entered into a Securities Exchange Agreement with Roosevelt Resources LP, which, if completed, will result in a change of control with Roosevelt partners owning 90% of shares.

• Gross profit margins exceeded 30% for the 11th consecutive quarter.

• Net income attributable to common stockholders for Q3 2025 was $856,000, a $2.5 million improvement year-over-year.

Financial highlights

• Q3 2025 product revenues were $1.3M, down 15% year-over-year, mainly due to discontinued GLA oil sales and a large customer sell-in in 2024.

• For the nine months ended September 30, 2025, revenues rose 3% to $4.0M, with Zola coconut water sales up 26%.

• Net income from continuing operations was $856K in Q3 2025, compared to a loss of $1.2M in Q3 2024.

• Net loss for the nine months was $1.0M, improved from a $3.0M loss in the prior year period.

• Operating expenses for Q3 2025 decreased 26% year-over-year to $2.5 million.

Outlook and guidance

• Management expresses substantial doubt about the ability to continue as a going concern due to insufficient cash to meet requirements for the next 12 months.

• Additional funding is required in the near term; options include debt, equity, or asset sales, but availability is uncertain.

• Pending business combination with Roosevelt Resources is ongoing, but timing is uncertain due to the federal government shutdown.

• Management continues to monitor external events impacting transaction timing.